Scientists discover new Alzheimer’s drug that repairs DNA damage and reduces brain inflammation

Scientists have discovered that a drug originally developed for spinal cord injuries can tackle several key features of Alzheimer’s disease, including DNA damage and inflammation. Already tested for initial safety in humans, the experimental treatment could offer a faster path toward therapies that target the disease at its roots.

The top 3

  1. Mechanism of Action: DNA Repair and Inflammation: KCL-286 acts as a retinoic acid receptor-beta (RARβ) agonist, modulating Vitamin A pathways to influence gene regulation. By activating this system, the small molecule facilitates the repair of DNA double-strand breaks—a severe form of genetic damage—while simultaneously suppressing inflammatory responses that contribute to neuron loss early in the disease progression.
  2. Development Path and Translational Potential: Originally developed for spinal cord injuries, KCL-286 leverages biological overlaps between central nervous system trauma and Alzheimer's. Because the drug has already completed Phase 1 human safety and tolerability trials, researchers suggest the timeline for further clinical testing may be significantly accelerated compared to new drug candidates.

Sources

Open the full topic